Latest From PowerVision Inc.
With the eye-care business set for its own stock exchange listings next month and the future of Sandoz the subject of much discussion, Novartis' plan to be a pure play pharma firm moves ever closer.
The arrival of a new generation of intraocular lenses and corneal inlays – designed to offer clearer, improved vision without the need for reading glasses – is expected to spur growth in the presbyopia market.
In the ophthalmic device sector, intraocular lens surgery is expanding way beyond the cataract market with paradigm shifting technology. The vast presbyopia market now has an FDA-approved "corneal inlay" option, micro invasive glaucoma surgery has created an entirely new device segment, and corneal cross-linking has the potential to transcend its role as an effective treatment for a corneal disease to possibly being the next big thing in the non-surgical treatment of refractive errors.
Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.
- Implantable Devices
- Surgical Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- PowerVision Inc.
- Senior Management
Barry Cheskin, Pres. & CEO
Matthew A Finzi, Chief Business Officer
Bryan Flaherty, PhD, VP, R&D
- Contact Info
Phone: (650) 620-9948
298 Harbor Blvd.
Belmont, CA 94002
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.